This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Solanezumab

Eli Lilly & Company

Drug Names(s): humanised m266, LY2062430

Description: Solanezumab is an antibody against beta-amyloid (targeting a portion in the middle of the molecule), a peptide that builds up and aggregates in Alzheimer's disease. Amyloid beta is thought to be involved in the nerve damage seen in the condition. Solanezumab is given as an infusion every 4 weeks.

Partners: PDL BioPharma, Inc.


Solanezumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug